Portal de Periódicos da CAPES

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

2019; Springer Nature; Volume: 33; Issue: 4 Linguagem: Inglês

10.1038/s41375-019-0426-8

1476-5551

Deepa Bhojwani, Richard Sposto, Nirali N. Shah, Vilmarie Rodriguez, Constance M. Yuan, Maryalice Stetler‐Stevenson, Maureen M. O’Brien, Jennifer L. McNeer, Amrana Quereshi, Aurélie Cabannes, Paul G. Schlegel, Claudia Rössig, Luciano Dalla‐Pozza, Keith J. August, Sarah Alexander, Jean‐Pierre Bourquin, Michel Zwaan, Elizabeth A. Raetz, Mignon L. Loh, Susan R. Rheingold,

Pharmaceutical studies and practices

We thank the research coordinators and following physicians at pediatric cancer centers for contributing data to this project: Prashant Hiwarkar and Jayashree Motwani, Birmingham Women’s and Children’s Hospital, UK; Kelly Malone, Children’s Hospital of Colorado, USA; Mylene Bassal, Children’s Hospital of Eastern Ontario, Canada; Yoav Messinger and Joanna Perkins, Children’s Hospital of Minnesota, USA; Van Huynh, Children’s Hospital of Orange County, USA; Richard Ho, Children’s Hospital at Vanderbilt, USA; Joanne Chuah and Jessa Morales, Children’s Hospital at Westmead, Australia; Donald Wells, Dell Children’s Hospital, USA; Nicolas Boissel, Hospital Saint-Louis, France; Tannie Huang, Kaiser Permanente, USA; Stacey Marjerrison, McMaster Children’s Hospital, Canada; William Carroll and Joanna Pierro, New York University Langone Medical Center, USA; Ajay Vora, Sheffield Children’s Hospital, UK; Donna Lancaster, The Royal Marsden Hospital, UK; Lucie Šrámková, University Hospital Motol, Czech Republic; Chatchawin Assanasen, University of Texas Health Science Center, San Antonio, USA; Rupert Handgretinger, University of Tübingen, Germany.